Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide

HIGHLIGHTS

• who: Takashi Kawahara from the A total of , mCRPC patients who received ABI and/ or ENZ at Yokohama City University, Nagoya University, Kitasato University, and affiliated hospitals between , and , were evaluatedAll patients were pathologically confirmed to have prostate cancer and received androgen deprivation therapy (ADT) but had refractory disease. CRPC was defined according to the Prostate Cancer Working Group , guidelines [9]. The patient characteristics, including initial prostate-specific antigen (PSA) level, initial metastatic status, Gleason score, observation period, time to CRPC, chemotherapy-nau00efve or not, age at baseline, PSA level at baseline, ALP level at baseline, LDH . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.